Table 1 Baseline clinical characteristics of the PD patients

Age in years

M (SD)

62.4 (8.4)

Disease duration in years

M (SD)

9.8 (4.9)

Sex

 Female

n (%)

28 (31)

 Male

n (%)

62 (69)

LEDD in mg

M (SD)

1068.2 (419.0)

H&Y stage medOFF

Md (IQR)

2.8 (2.5–4.0)

H&Y stage 1

n (%)

0 (0)

H&Y stage 1.5

n (%)

0 (0)

H&Y stage 2

n (%)

20 (22)

H&Y stage 2.5

n (%)

25 (28)

H&Y stage 3

n (%)

22 (24)

H&Y stage 4

n (%)

21 (23)

H&Y stage 5

n (%)

2 (2)

UPDRS-III medOFF

M (SD)

37.0 (11.0)

UPDRS-III medOFF PIGD

Md (IQR)

4.8 (2.8–6.3)

Levodopa Response in %

M (SD)

48.1 (15.8)

MoCA Total

Md (IQR)

25.0 (24.0–27.0)

PANDA Total

Md (IQR)

22.0 (18.0–26.0)

HADS Anxiety T-values

Md (IQR)

49.0 (42.6–55.9)

HADS Depression T-values

Md (IQR)

48.9 (45.3–56.3)

PDQ-39 SI

Md (IQR)

24.0 (14.4–35.6)